Biophytis SA

ALBPS

Company Profile

  • Business description

    Biophytis SA is a France-based biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Its drug candidate BIO101, is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and DMD.

  • Contact

    BC 9, Batiment A 4eme etage
    4 pace Jussieu
    Sorbonne University
    Paris75005
    FRA

    T: +33 144272300

    https://www.biophytis.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    24

Stocks News & Analysis

stocks

Tesla’s stock is in trouble, but this fund manager sees a comeback in 2026

Tesla’s challenges echo past issues the company has overcome, says Zevenbergen’s Joe Dennison.
stocks

Cheap ASX energy play boasts strong cash flows and balance sheet

Markets appear overly bearish on the company despite the company having attracting growth options.
stocks

Market overreacts to earnings miss from moated ASX retailer

Our forecast recovery is off to a slow start but the sell-off appears to have gone too far.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,245.0066.30-0.71%
CAC 407,843.04126.65-1.59%
DAX 4024,273.1289.97-0.37%
Dow JONES (US)45,351.92279.82-0.61%
FTSE 1009,321.4012.200.13%
HKSE25,829.91490.771.94%
NASDAQ21,524.0327.500.13%
Nikkei 22542,807.82174.530.41%
NZX 50 Index13,079.5036.740.28%
S&P 5006,456.2210.69-0.17%
S&P/ASX 2008,972.4071.70-0.79%
SSE Composite Index3,883.5657.801.51%

Market Movers